Abstract：
UNASSIGNED: To compare the number of oocytes retrieved and clinical outcomes of ovulation induction in an older population treated with in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) (IVF/ICSI) using different rFSH options and the effectiveness of antagonist treatment to induce ovulation using gonadotropin-releasing hormone agonists (GnRH-a) in combination with an human chorionic gonadotropin (HCG) trigger.
UNASSIGNED: A total of 132 fresh cycles were selected for this study, which were treated with IVF/ICSI in our hospital from March 2022 to December 2022. Observations were made according to different subgroups and the effects of different triggering methods on the number of oocytes obtained, embryo quality, and clinical outcomes.
UNASSIGNED: The initial gonadotropin (Gn) dose, the number of oocytes, and the number of MII oocytes were higher in group A than in group B (p < .05), and the clinical pregnancy rate was 29.41% in group A. Group B had a clinical pregnancy rate of 27.5%. The double-trigger group was superior to the HCG-trigger group in terms of the number of 2PN, the number of viable embryos, and the number of high-quality embryos (p < .05). The use of a double-trigger regimen (OR = 0.667, 95%CI (0.375, 1.706), p = .024) was a protective factor for the clinical pregnancy rate, whereas AFC (OR = 0.925, 95%CI (0.867, 0.986), p = .017) was an independent factor for the clinical pregnancy rate.
UNASSIGNED: The use of a dual-trigger regimen of GnRH-a in combination with HCG using an appropriate antagonist improves pregnancy outcomes in fresh embryo transfer cycles in older patients.
UNASSIGNED: A total of 132 fresh cycles were selected for this study, which were treated with IVF/ICSI in our hospital from March 2022 to December 2022. Observations were made according to different subgroups and the effects of different triggering methods on the number of oocytes obtained, embryo quality, and clinical outcomes.
UNASSIGNED: The initial gonadotropin (Gn) dose, the number of oocytes, and the number of MII oocytes were higher in group A than in group B (p < .05), and the clinical pregnancy rate was 29.41% in group A. Group B had a clinical pregnancy rate of 27.5%. The double-trigger group was superior to the HCG-trigger group in terms of the number of 2PN, the number of viable embryos, and the number of high-quality embryos (p < .05). The use of a double-trigger regimen (OR = 0.667, 95%CI (0.375, 1.706), p = .024) was a protective factor for the clinical pregnancy rate, whereas AFC (OR = 0.925, 95%CI (0.867, 0.986), p = .017) was an independent factor for the clinical pregnancy rate.
UNASSIGNED: The use of a dual-trigger regimen of GnRH-a in combination with HCG using an appropriate antagonist improves pregnancy outcomes in fresh embryo transfer cycles in older patients.
摘要：
■比较使用不同rFSH选择的体外受精（IVF）/卵胞浆内单精子注射（ICSI）（IVF/ICSI）治疗的老年人群的卵母细胞数量和排卵诱导的临床结果以及使用促性腺激素释放激素（GnRH-a）与人绒毛膜促性腺激素（HCG）引发剂的拮抗剂治疗诱导排卵的有效性。
■本研究共选择了132个新鲜周期，2022年3月至2022年12月在我们医院接受IVF/ICSI治疗。根据不同的亚组和不同的触发方法对获得的卵母细胞数量的影响进行观察，胚胎质量,和临床结果。
■促性腺激素（Gn）的初始剂量，卵母细胞的数量，A组MII卵母细胞数高于B组(p<0.05),A组临床妊娠率为29.41%,B组临床妊娠率为27.5%。在2PN的数量方面，双触发组优于HCG触发组，存活胚胎的数量,和高质量胚胎的数量（p<0.05）。使用双触发方案（OR=0.667，95CI（0.375，1.706），p=.024)是临床妊娠率的保护因素，而AFC(OR=0.925，95CI(0.867，0.986)，p=.017）是临床妊娠率的独立因素。
■GnRH-a与HCG联合使用适当的拮抗剂可改善老年患者新鲜胚胎移植周期的妊娠结局。
■本研究共选择了132个新鲜周期，2022年3月至2022年12月在我们医院接受IVF/ICSI治疗。根据不同的亚组和不同的触发方法对获得的卵母细胞数量的影响进行观察，胚胎质量,和临床结果。
■促性腺激素（Gn）的初始剂量，卵母细胞的数量，A组MII卵母细胞数高于B组(p<0.05),A组临床妊娠率为29.41%,B组临床妊娠率为27.5%。在2PN的数量方面，双触发组优于HCG触发组，存活胚胎的数量,和高质量胚胎的数量（p<0.05）。使用双触发方案（OR=0.667，95CI（0.375，1.706），p=.024)是临床妊娠率的保护因素，而AFC(OR=0.925，95CI(0.867，0.986)，p=.017）是临床妊娠率的独立因素。
■GnRH-a与HCG联合使用适当的拮抗剂可改善老年患者新鲜胚胎移植周期的妊娠结局。
